Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in
KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have
previously not received chemotherapy. This study will also examine the potential toxicities,
progression-free and overall survival in this population.